510(k) device
Exablate Model 2100V1
Insightec, Ltd. · High Intensity Ultrasound System For Prostate Tissue Ablation (PLP, Class II) · First FDA decision Nov 23, 2021, newest Oct 30, 2023Prostate cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
120
Naming "Exablate"
MAUDE reports
260
Brand "Exablate", since 2015
PubMed studies
78
Mentioning "Exablate"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Exablate Model 2100V1
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K231378 · Decided Oct 30, 2023 · 171 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Laser Ablation of the ProstateLocal determinationIn effectL34090CGS Administrators, LLCUpdated Mar 25, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38705Noridian Healthcare Solutions, LLCUpdated Feb 23, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38549Palmetto GBAUpdated Oct 24, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38682WPS Insurance CorporationUpdated Oct 21, 2025
- Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorProposed local determinationProposedDL37421National Government Services, Inc.Updated Sep 18, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38726First Coast Service Options, Inc.Updated Mar 14, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38712Novitas Solutions, Inc.Updated Mar 14, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Exablate", any status and sponsor, newest update first.
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT07113665 · 10 participants (planned) · Start Sep 5, 2025 · Primary completion Aug 2028
Device: ExAblate Neuro 4000 · For: Anorexia Nervosa (DSM-IV Revised Criteria)
Sites: Toronto, Canada
119 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Exablate", and for the whole product code for context.
This brand
260 reports: 2 malfunction, 253 injury, 5 death
Whole product code PLP
33 reports: 1 malfunction, 31 injury, 1 death
Newest reports for this brand
- Exablate 4000Injury
9615058-2026-00025 · Received Oct 21, 2026 · Event dated Jun 25, 2026
Device type: Mr-Guided Focused Ultrasound System (POH)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Fatigue; Balance Problems; Decreased Appetite
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Exablate"[tiab]. The summary above synthesizes these.
- Volumetric hyperthermia delivery using the ExAblate Body MR-guided focused ultrasound system.
Kim K, Gupta P, Narsinh K, et al. · Int J Hyperthermia · 2024Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Exablate Neuro for essential tremor.
Med Lett Drugs Ther · 2017
- Device profile of exAblate Neuro 4000, the leading system for brain magnetic resonance guided focused ultrasound technology: an overview of its safety and efficacy in the treatment of medically refractory essential tremor.
Jameel A, Bain P, Nandi D, et al. · Expert Rev Med Devices · 2021Review
- Transcranial focused ultrasound phase correction using the hybrid angular spectrum method.
Leung SA, Moore D, Webb TD, et al. · Sci Rep · 2021Research Support, N.I.H., Extramural
- A phase 1 open-label trial evaluating focused ultrasound unilateral anterior thalamotomy for focal onset epilepsy.
Krishna V, Mindel J, Sammartino F, et al. · Epilepsia · 2023Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array.
Salgaonkar VA, Prakash P, Rieke V, et al. · Med Phys · 2014Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparison between MR and CT imaging used to correct for skull-induced phase aberrations during transcranial focused ultrasound.
Leung SA, Moore D, Gilbo Y, et al. · Sci Rep · 2022Research Support, N.I.H., Extramural
- Sonoablation and application of MRI guided focused ultrasound in a preclinical model.
Zibly Z, Graves CA, Harnof S, et al. · J Clin Neurosci · 2014
- Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastoma.
McDannold N, Wen PY, Reardon DA, et al. · J Control Release · 2024Research Support, N.I.H., Extramural
- Echo-Focusing in Transcranial Focused Ultrasound Thalamotomy for Essential Tremor: A Feasibility Study.
Jones RM, Huang Y, Meng Y, et al. · Mov Disord · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Sonication strategies toward volumetric ultrasound hyperthermia treatment using the ExAblate body MRgFUS system.
Kim K, Zubair M, Adams M, et al. · Int J Hyperthermia · 2021Research Support, N.I.H., Extramural
- Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study.
Quinn SD, Vedelago J, Regan L, et al. · J Ther Ultrasound · 2013
Other devices of this type
Also filed under product code PLP.
- TULSA-PRO SystemProfound Medical, Inc. · 510(k) 2023
- Focal One®Edap Technomed, Inc. · 510(k) 2025
- Tulsa Pro System (Pad-105)Profound Medical, Inc. · 510(k) 2024
- Ablatherm FusionEdap Technomed, Inc. · 510(k) 2017
- SonablateSonacare Medical, LLC · 510(k) 2016
- Ablatherm Integrated ImagingEdap Technomed, Inc. · 510(k) 2015
- Sonablate 450Sonacare Medical, LLC · De Novo 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.